Retatrutide and trizepatide constitute a novel class of medications that target both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These combined receptor https://tayavhfo628270.blue-blogs.com/46549979/new-glp-1-and-gip-receptor-agonists-retatrutide-and-trizepatide